| Testosterone group (n = 49) | Placebo group (n = 51) | P value |
---|---|---|---|
Age, years | 54.3 (47.3–59.8) | 52.8 (47.6–60.1) | 0.93 |
Weight, kg | 118.3 (15.7) | 120.7 (19.6) | 0.51 |
BMI, kg/m2 | 37.5 (34.9–40.5) | 37.3 (34.7–41.6) | 0.60 |
Waist circumference, cm | 124 (118–131) | 123 (117–136) | 0.62 |
SBP, mmHg | 135 (14) | 130 (13) | 0.06 |
DBP, mmHg | 80 (78–88) | 80 (78–85) | 0.85 |
Handgrip, kg | 44 (41–50) | 46 (40–55) | 0.65 |
Fat mass, kg | 44.3 (10.0) | 46.4 (10.6) | 0.30 |
Fat mass, % | 38.8 (33.5–42.3) | 38.9 (36.0–43.5) | 0.208 |
Lean mass, kg | 68.1 (7.3) | 67.4 (9.1) | 0.67 |
ALM/height2, kg/m2 | 9.7 (1.0) | 9.6 (0.8) | 0.35 |
VAT area, mm2 | 25,088 (8617) | 24,836 (9557) | 0.89 |
Ischemic heart diseasea | 6 (12.2Â %) | 6 (11.8Â %) | 0.94 |
Diabetes | 10 (20.4Â %) | 12 (23.5Â %) | 0.71 |
Metformin | 3 (6.1Â %) | 3 (5.9Â %) | 0.96 |
Statin use | 14 (28.6Â %) | 15 (29.4Â %) | 1.0 |
Steps per day | 6378 (4761–7543) | 6371 (4816–7440) | 0.79 |
Activity (%/day) | 14.2 (5.7) | 13.5 (4.5) | 0.49 |
Physical performance test (sec) | 36.2 (32.5–41.6) | 37.1 (33.1–40.5) | 0.40 |
TT, nmol/L, ECLIA | 8.2 (2.5) | 8.4 (2.3) | 0.65 |
TT, nmol/L, LCMS/MS | 6.8 (2.0) | 7.0 (1.6) | 0.55 |
cFT, pmol/L, ECLIA | 195 (58) | 208 (55) | 0.23 |
cFT, pmol/L, LCMS/MS | 159 (46) | 172 (44) | 0.15 |
SHBG, nmol/L | 25 (18–31) | 21 (17–26) | 0.17 |
LH, IU/L | 4.5 (3.3–5.6) | 4.2 (3.1–5.2) | 0.70 |
Fasting glucose, mmol/L | 5.8 (5.3–6.1) | 5.8 (5.4–6.4) | 0.72 |
HOMA-IR | 3.3 (1.0) | 3.6 (1.1) | 0.27 |
HbA1c, % | 6.0 (5.6–6.2) | 6.1 (5.8–6.5) | 0.23 |
Total cholesterol, mmol/L | 5.1 (4.3–5.6) | 4.8 (4.4–5.7) | 0.60 |
LDL-c, mmol/L | 2.9 (0.9) | 2.9 (1.0) | 0.99 |
HDL-c, mmol/L | 1.1 (1.0–1.3) | 1.2 (1.0–1.3) | 0.58 |
Triglycerides, mmol/L | 1.9 (1.4–2.4) | 1.7 (1.2–2.5) | 0.38 |
Haematocrit | 0.43 (0.02) | 0.44 (0.02) | 0.003 |
Haemoglobin, g/L | 148 (8) | 152 (9) | 0.014 |
PSA, μg/L | 0.7 (0.5–1.1) | 0.7 (0.5–1.2) | 0.79 |